var audioList=[{"title":"恒瑞医药临床试验进展公告点评（中泰证券江琪）","urlAudio":"https://fdfs.xmcdn.com/group58/M00/83/CE/wKgLc1yymyeT6GpqADTuvssHOac805.m4a"},{"title":"恒瑞医药三季报点评（中金.邹朋）","urlAudio":"https://fdfs.xmcdn.com/group49/M06/06/06/wKgKl1vUC9uT81DfAB4cGqbA9rg556.m4a"},{"title":"恒瑞医药砒洛替尼高效获批点评（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group47/M01/BA/BA/wKgKk1uUgarjAWBsACA1jtgCgTI969.m4a"},{"title":"恒瑞医药首个胰岛素获批临床（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group48/M07/96/27/wKgKnFuUgtHBwOxKAB3D_8LUFl4507.m4a"},{"title":"恒瑞医药-沪港通资金重点吸纳2017-01","urlAudio":"https://fdfs.xmcdn.com/group24/M05/69/0D/wKgJMFh05TuSAFJdABfBE_Iy4rg689.m4a"},{"title":"恒瑞医药-沪港通资金重点吸纳（群益）2017-01","urlAudio":"https://fdfs.xmcdn.com/group23/M00/71/B2/wKgJL1h2JP-C9egzABVFP499aoI306.m4a"},{"title":"恒瑞医药及新兴生物制药公司有进入3.0时代的野心（雪球）","urlAudio":"https://fdfs.xmcdn.com/group24/M09/1D/D3/wKgJNViNcoeCLY1TAC8N2kCA7SI855.m4a"},{"title":"恒瑞医药-卡泊芬净获批 首仿药进入收获期（海通）2017-02","urlAudio":"https://fdfs.xmcdn.com/group22/M05/6D/90/wKgJM1ibBcGAdl8tABvmw149E5E391.m4a"},{"title":"恒瑞医药-海外市场开疆辟土 制剂出口又下一城（国泰）2017-02","urlAudio":"https://fdfs.xmcdn.com/group25/M00/6D/72/wKgJNlibB2uCmPqgABaSlrbj_PQ559.m4a"},{"title":"恒瑞医药-ANDA文号又有斩获 期待后续品种获批（兴业）2017-02","urlAudio":"https://fdfs.xmcdn.com/group25/M03/6D/7E/wKgJMVibCCGQdbzBAA4fkvttR1Q806.m4a"},{"title":"恒瑞医药-制剂出口再添新兵 国内首仿优先审评有所突破（东兴）","urlAudio":"https://fdfs.xmcdn.com/group23/M00/72/56/wKgJL1icVjPQrUiwABVILtZUK7o458.m4a"},{"title":"恒瑞医药-多西他赛获批 制剂出口迎来密集收获期（海通）","urlAudio":"https://fdfs.xmcdn.com/group25/M09/9F/4B/wKgJMViqyG2hUeh5AB5T6EIUbLE318.m4a"},{"title":"恒瑞医药-2017年或成恒瑞海外ANDA+收入双爆发年（东兴）","urlAudio":"https://fdfs.xmcdn.com/group24/M0A/A2/A9/wKgJMFisG_DhbSb8ABCc4Vt32rE777.m4a"},{"title":"恒瑞医药-ANDA文号密集获批（兴业）","urlAudio":"https://fdfs.xmcdn.com/group24/M06/A9/82/wKgJNVitparw2wPsAAuSIHCUFNQ610.m4a"},{"title":"恒瑞医药2016年度报告摘要","urlAudio":"https://fdfs.xmcdn.com/group25/M00/E8/BB/wKgJNljDe1TzlWRJAYm7HH3Xmtk382.m4a"},{"title":"恒瑞医药16年报跟踪分析（御风飞翔）","urlAudio":"https://fdfs.xmcdn.com/group24/M03/E4/DF/wKgJNVjD-aChXRnKAFqtTproJRk208.m4a"},{"title":"恒瑞医药16年报:业绩符合预期 国际化进程加速（平安）","urlAudio":"https://fdfs.xmcdn.com/group26/M0B/0A/75/wKgJWFjH1RigeSSBACiCX5VeuB0824.m4a"},{"title":"恒瑞医药16年报:肿瘤、麻醉、造影、出口四金刚出类拔萃（东兴）","urlAudio":"https://fdfs.xmcdn.com/group26/M0A/0B/5B/wKgJWFjH2uvTOy07ABUgh5JXZdA180.m4a"},{"title":"恒瑞医药16年报：创新和国际化战略助力持续成长（招商）","urlAudio":"https://fdfs.xmcdn.com/group26/M04/0B/90/wKgJRljH3D6SIksGAB7NyFccmvg098.m4a"},{"title":"恒瑞医药16年报:业绩增长稳健 期待新品放量（中金）","urlAudio":"https://fdfs.xmcdn.com/group26/M05/10/AE/wKgJRljH9jjTvcZ2AB5PgUK6bbA129.m4a"},{"title":"恒瑞医药16年报:创新和国际化值得期待（广发）","urlAudio":"https://fdfs.xmcdn.com/group26/M08/10/B3/wKgJRljH9lOQ-PW7AB3OSIi4s84404.m4a"},{"title":"恒瑞医药16年报:创新速度加快（西南）","urlAudio":"https://fdfs.xmcdn.com/group26/M08/10/B6/wKgJRljH9l-DuQo7ACC8pmar3ak274.m4a"},{"title":"恒瑞医药16年报:产品结构优化实现多元增长 下调预测（国泰）","urlAudio":"https://fdfs.xmcdn.com/group26/M09/10/B8/wKgJWFjH9m6g0mE4ABd5Hvk1QsA890.m4a"},{"title":"恒瑞医药16年报:研发产品线为长期增长奠定基础（中泰）","urlAudio":"https://fdfs.xmcdn.com/group26/M08/10/BB/wKgJRljH9nvgDDdWACMIBnulqsU366.m4a"},{"title":"恒瑞医药16年报:主业稳定增长 创新+国际化顺利开展（国联）","urlAudio":"https://fdfs.xmcdn.com/group26/M04/10/BD/wKgJWFjH9onxoppdABvoO4kyRvg541.m4a"},{"title":"恒瑞医药16年报:高增速产品拉动业绩增长 17-19迎新品爆（海通）","urlAudio":"https://fdfs.xmcdn.com/group26/M04/10/C4/wKgJRljH9qfhlx_2ACAj7GjKDhQ035.m4a"},{"title":"恒瑞医药16年报：创新药+制剂出口引领成长 下调业绩预测（申万）","urlAudio":"https://fdfs.xmcdn.com/group26/M04/10/C5/wKgJWFjH9rfC5nt1ACYPXLYgQMc411.m4a"},{"title":"恒瑞医药16年报:业绩增长稳健 创新基因驱动长远发展（爱建）","urlAudio":"https://fdfs.xmcdn.com/group26/M0A/10/CC/wKgJWFjH9tvhHM9ZAC9EMKslR9M650.m4a"},{"title":"恒瑞医药16年报：创新和海外业绩支撑未来（国金）","urlAudio":"https://fdfs.xmcdn.com/group26/M01/17/AE/wKgJRljJRDngPQNxABx1MTy5Qfw808.m4a"},{"title":"恒瑞医药16年报:稳健前行（华融）","urlAudio":"https://fdfs.xmcdn.com/group27/M0A/13/9A/wKgJR1jJRWiAOveGABL7V1ybIw4348.m4a"},{"title":"恒瑞医药16年报:业绩稳健增长 优先审评和海外申报落地（兴业）","urlAudio":"https://fdfs.xmcdn.com/group26/M05/19/65/wKgJRljJWyOxJdqzAA8fFk_87OM968.m4a"},{"title":"恒瑞医药16年报:业绩不及预期 关键临床试验如期推进gh","urlAudio":"https://fdfs.xmcdn.com/group26/M0B/19/79/wKgJRljJXI7iwM9zAB1mBmvUJOk753.m4a"},{"title":"恒瑞医药-卡泊芬净海外获批 发展再添动力（爱建）","urlAudio":"https://fdfs.xmcdn.com/group27/M04/1E/80/wKgJR1jKfl-SMionACeBZ6r-afs072.m4a"},{"title":"恒瑞医药-卡泊芬净在英国德国获批 有助首仿药国内推广（中泰）","urlAudio":"https://fdfs.xmcdn.com/group27/M05/24/5A/wKgJR1jLHJzQTejCAB6F1L-xVO4563.m4a"},{"title":"恒瑞医药-业绩稳定增长 创新药及制剂出口值得期待（财富）","urlAudio":"https://fdfs.xmcdn.com/group27/M05/24/5B/wKgJR1jLHK7CcS-DACAWuK593lw101.m4a"},{"title":"恒瑞医药-国际化提升发展弹性 创新药推倒业绩增长（东吴）","urlAudio":"https://fdfs.xmcdn.com/group27/M0B/33/90/wKgJW1jMtrbgZWIUAAuB-Z-pOQA308.m4a"},{"title":"恒瑞医药过渡期的探讨（舒颜）","urlAudio":"https://fdfs.xmcdn.com/group26/M04/3C/64/wKgJWFjNHIGyyflLAFbPls6J3Rg562.m4a"},{"title":"恒瑞医药16年报电话会议（广发）","urlAudio":"https://fdfs.xmcdn.com/group27/M07/38/80/wKgJW1jNIUbC8MlVAG8x5xpno1k981.m4a"},{"title":"恒瑞医药利润真的低于预期吗？（Stevevai1983）","urlAudio":"https://fdfs.xmcdn.com/group26/M0A/41/E9/wKgJWFjNxUqgLx1eABAM-D2C1Ws595.m4a"},{"title":"恒瑞医药的格局 创新能力及发展空间（Stevevai1983）","urlAudio":"https://fdfs.xmcdn.com/group27/M04/3E/2B/wKgJR1jN0kCT7za6ABLMWmunbi0856.m4a"},{"title":"恒瑞医药16年报:平稳增长可延续（东财）","urlAudio":"https://fdfs.xmcdn.com/group27/M05/C0/80/wKgJR1jaTjjTZPf4AAuJT49qXb4150.m4a"},{"title":"恒瑞医药股东大会暨交流纪要1（亿利达）","urlAudio":"https://fdfs.xmcdn.com/group26/M0B/A3/7D/wKgJRljwQ5vi8Z38AEhp0VBmeMs341.m4a"},{"title":"恒瑞医药股东大会暨交流纪要2（亿利达）","urlAudio":"https://fdfs.xmcdn.com/group27/M00/9F/15/wKgJW1jwRQqC2VpbACkylRyfYBY010.m4a"},{"title":"恒瑞医药董事长孙飘扬谈创新转型的机遇和挑战（贝壳社）","urlAudio":"https://fdfs.xmcdn.com/group27/M04/26/50/wKgJR1j7a2jB1rBsAHNAE6_-JTk992.m4a"},{"title":"恒瑞医药一季报：创新药布局继续加强（国金）","urlAudio":"https://fdfs.xmcdn.com/group27/M05/27/0C/wKgJR1j7c1DjuC6uABauffbLBwI173.m4a"},{"title":"恒瑞医药一季报：业绩稳健持续 产品厚积薄发（国泰）","urlAudio":"https://fdfs.xmcdn.com/group27/M06/27/27/wKgJR1j7dLrjEjoyABJcv2zkJUM386.m4a"},{"title":"恒瑞医药一季报：阿帕进入医保谈判目录（中金）","urlAudio":"https://fdfs.xmcdn.com/group26/M02/2B/00/wKgJRlj7dbXxA-a3ABfM0zYGevw707.m4a"},{"title":"恒瑞医药-IDO抑制剂研发进度领先（中泰）","urlAudio":"https://fdfs.xmcdn.com/group27/M00/FC/C4/wKgJW1kLGZXTaEkGABp0tJ4tF7E129.m4a"},{"title":"恒瑞医药-IDO抑制剂获批进入US临床（广发）","urlAudio":"https://fdfs.xmcdn.com/group27/M06/0D/9B/wKgJR1kMW2Txc7rnAB0K-GvBroc454.m4a"},{"title":"恒瑞医药-大专科 强创新 稳出口（国泰）","urlAudio":"https://fdfs.xmcdn.com/group29/M08/36/B8/wKgJXVkdppTTkRa0ABW9qGJ48Lk838.m4a"},{"title":"恒瑞医药-19K进入优先审评 阿帕替尼后又一个10亿级别创新药","urlAudio":"https://fdfs.xmcdn.com/group29/M01/EA/CC/wKgJXVkljpjzYvnYAEGPB06xGyU046.m4a"},{"title":"恒瑞医药-重磅升白药纳入优先审评 新药研发稳步推进（中泰）","urlAudio":"https://fdfs.xmcdn.com/group29/M0A/EC/9B/wKgJWVkllZLxeQvDACUYqeI9x3U725.m4a"},{"title":"恒瑞医药-19K获优先审评 过10亿重磅获批可期（西南）","urlAudio":"https://fdfs.xmcdn.com/group28/M02/88/32/wKgJXFkpYsLycsMlACB0skQqWk0901.m4a"},{"title":"恒瑞医药2016年报之一主要业务和经营模式","urlAudio":"https://fdfs.xmcdn.com/group28/M01/C7/9C/wKgJXFk6jcDzO7axADGp_3sk5fs278.m4a"},{"title":"恒瑞医药16年报之二行业情况 行业地位及业绩驱动因素","urlAudio":"https://fdfs.xmcdn.com/group29/M06/C3/74/wKgJXVk6jw3C7-NeACP4128fDFw757.m4a"},{"title":"恒瑞医药一六年报之三核心竞争力分析","urlAudio":"https://fdfs.xmcdn.com/group29/M09/C3/FA/wKgJWVk6kBvBo-1qABwqTZWkItM294.m4a"},{"title":"恒瑞医药16年报之四经营情况讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group28/M09/C7/F6/wKgJXFk6ksXinJN1AD9YNeAzIwc568.m4a"},{"title":"恒瑞医药16年报之五行业经营性信息分析","urlAudio":"https://fdfs.xmcdn.com/group29/M0A/C5/28/wKgJWVk6nkvx5cm9AF1bEvQNT6A221.m4a"},{"title":"恒瑞医药一六年报之六研发总体情况","urlAudio":"https://fdfs.xmcdn.com/group29/M08/C5/44/wKgJWVk6n2SgRrSPAB_wiUloK7w915.m4a"},{"title":"恒瑞石药紫杉醇进入审批绿色通道（21世纪经济报道）","urlAudio":"https://fdfs.xmcdn.com/group28/M04/C7/01/wKgJSFlMmgXgNjPjAEEQvfUfg-E123.m4a"},{"title":"恒瑞医药-白蛋白紫杉醇获优先审评研发进展顺利","urlAudio":"https://fdfs.xmcdn.com/group28/M06/DD/66/wKgJSFlOUF2hCLgFABoVRORMEBM104.m4a"},{"title":"恒瑞医药-紫杉醇重磅剂型进优先审评有望获批首仿（西南）","urlAudio":"https://fdfs.xmcdn.com/group28/M09/0F/DB/wKgJSFlR5WyAsm6PABxiG7zfKdE471.m4a"},{"title":"恒瑞医药转身创新药龙头 市值一哥怎样炼成？","urlAudio":"https://fdfs.xmcdn.com/group28/M01/95/7F/wKgJXFlbpITQE_-PAJHo3WVihkQ046.m4a"},{"title":"细看恒瑞医药财务数据（money83）","urlAudio":"https://fdfs.xmcdn.com/group2/M02/0B/6B/wKgJRVlqPmLxcugPAE-LE-QsMEY600.m4a"},{"title":"恒瑞医药-制剂国际化典范 中美区日等市场协同推进","urlAudio":"https://fdfs.xmcdn.com/group29/M06/66/E8/wKgJXVlr8w_zN5eCADFsVAhZRj4824.m4a"},{"title":"恒瑞医药-地氟烷欧盟获批 国内进入优先审评（东兴）","urlAudio":"https://fdfs.xmcdn.com/group29/M04/69/44/wKgJWVlstsjCivgTABHULxCS4IA354.m4a"},{"title":"恒瑞医药-地氟烷在欧洲获批上市（中泰）","urlAudio":"https://fdfs.xmcdn.com/group22/M03/EF/45/wKgJLllsyofxlSYDABfaC0VNMIY154.m4a"},{"title":"恒瑞医药-地氟烷欧盟获批上市 制剂出口步伐加快（西南）","urlAudio":"https://fdfs.xmcdn.com/group31/M0A/0A/31/wKgJSVluHIewwseOABzqqnRzEH0550.m4a"},{"title":"恒瑞医药-地氟烷欧洲获批 期待未来中美市场表现（海通）","urlAudio":"https://fdfs.xmcdn.com/group30/M02/11/94/wKgJXlluHaajX1RCABeE3maEW8U946.m4a"},{"title":"恒瑞医药-吸入用地氟烷海外获批 制剂出口稳步推进（上海证券）","urlAudio":"https://fdfs.xmcdn.com/group30/M01/3D/9C/wKgJXllve1aTPfuCACnwA_7Uuws606.m4a"},{"title":"恒瑞医药强者恒强（国信）","urlAudio":"https://fdfs.xmcdn.com/group30/M05/85/92/wKgJXllyA1ai0o2nAB3SroiyBzs512.m4a"},{"title":"恒瑞医药-阿帕替尼降价35%纳入医保（增持）","urlAudio":"https://fdfs.xmcdn.com/group31/M07/45/77/wKgJSVlyC92ThZIyABkekOCMTGo808.m4a"},{"title":"恒瑞医药-阿帕替尼新进国家医保 放量或将加速（西南）","urlAudio":"https://fdfs.xmcdn.com/group30/M06/15/FD/wKgJXll3L53AdKnpACRlgzI29dI324.m4a"},{"title":"从技术员到行业首富1（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group31/M06/38/38/wKgJX1mDC_7g69_nAEr7qeB2PII971.m4a"},{"title":"从技术员到行业首富2（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group31/M02/38/54/wKgJX1mDDSuCjtCYACeFzXjyZCk198.m4a"},{"title":"从技术员到行业首富3（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group31/M09/38/6C/wKgJX1mDDlXTpASoACMMbAIk-nQ118.m4a"},{"title":"从技术员到行业首富4（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group31/M0B/38/AA/wKgJSVmDD8Dy1WIuACieRfc5xbo863.m4a"},{"title":"从技术员到行业首富5（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group30/M0A/6D/AB/wKgJXlmDE0_Bne7LACnFbUR52nw915.m4a"},{"title":"从技术员到行业首富6（迟玉德）","urlAudio":"https://fdfs.xmcdn.com/group30/M08/6E/21/wKgJXlmDFbeDxXlJADTvAX0UwdU254.m4a"},{"title":"恒瑞医药-海曲泊帕有望成免疫线重磅品种（交银）","urlAudio":"https://fdfs.xmcdn.com/group30/M09/82/B1/wKgJXlmD6H7ztVuWAAiTm_Zneo0321.m4a"},{"title":"恒瑞医药-三大品种将开展临床试验 创新药有望陆续上市（中泰）","urlAudio":"https://fdfs.xmcdn.com/group31/M09/82/75/wKgJSVmIU1-xPM99ACE8aHBzoEY997.m4a"},{"title":"恒瑞医药多品种临床获批 创新药进入收获阶段（平安）","urlAudio":"https://fdfs.xmcdn.com/group31/M04/82/BE/wKgJSVmIVvnB74x2ADAO1kwh-44835.m4a"},{"title":"恒瑞医药-多个新品获批临床 在研产品线进一步夯实（中金）","urlAudio":"https://fdfs.xmcdn.com/group30/M0B/01/27/wKgJXlmIWKDQga2nACLRr6I0gj0584.m4a"},{"title":"恒瑞医药系列之麻醉药篇：小专科大品种 战略决定高度（国信）","urlAudio":"https://fdfs.xmcdn.com/group31/M0A/95/7D/wKgJSVmJoB2zQcO6AB4KfDdcUjw717.m4a"},{"title":"恒瑞开始进军脂肪肝领域（菜菜）","urlAudio":"https://fdfs.xmcdn.com/group30/M02/97/95/wKgJXlmNkjehqaQQAEf3Rs19Jxk634.m4a"},{"title":"恒瑞制剂国际化再下一城（E药经理人）","urlAudio":"https://fdfs.xmcdn.com/group21/M09/EF/B7/wKgJLVmU153wlnXRAGresVKcQ9k536.m4a"},{"title":"恒瑞医药2017半年报（东兴）","urlAudio":"https://fdfs.xmcdn.com/group33/M03/F5/8B/wKgJTFmoJi6AQpatAA5UcSopRNw187.m4a"},{"title":"恒瑞医药2017年半年报（平安）","urlAudio":"https://fdfs.xmcdn.com/group33/M02/F5/B6/wKgJTFmoKXXjGleQACBu03uJRRQ606.m4a"},{"title":"恒瑞医药2017年半年报点评（国信）","urlAudio":"https://fdfs.xmcdn.com/group30/M0B/97/37/wKgJXlmry2aQhFjiABqZbAWsXiw901.m4a"},{"title":"恒瑞医药2017年半年报点评（上海）","urlAudio":"https://fdfs.xmcdn.com/group33/M06/17/FB/wKgJnVmsEmnzM2YzACPqKLvMEvw830.m4a"},{"title":"恒瑞医药2017年半年报点评（国联）","urlAudio":"https://fdfs.xmcdn.com/group32/M02/17/80/wKgJnFmsFMqSUlmZAByYcWTOCmE832.m4a"},{"title":"恒瑞医药17年半年报（申万）","urlAudio":"https://fdfs.xmcdn.com/group32/M02/1D/F9/wKgJS1mtJiriZ2W2ACKJu3vG9tY627.m4a"},{"title":"恒瑞医药17年半年报点评（国泰）","urlAudio":"https://fdfs.xmcdn.com/group33/M09/1F/2F/wKgJTFmtJxfAjqS2ABcFHOhvOgI552.m4a"},{"title":"恒瑞医药17年半年报点评（兴业）","urlAudio":"https://fdfs.xmcdn.com/group31/M02/9D/5B/wKgJX1mtJ7HQwNcOAA0r0uGdCLM728.m4a"},{"title":"恒瑞医药点评（中泰）","urlAudio":"https://fdfs.xmcdn.com/group31/M00/47/DA/wKgJSVmurOWCc_PNABN8kHIRlfI201.m4a"},{"title":"恒瑞医药17年半年报点评（东北）","urlAudio":"https://fdfs.xmcdn.com/group31/M06/C8/28/wKgJX1mxWFTDBKlLABjJZOt7zE8995.m4a"},{"title":"恒瑞医药17年半年报点评（民生）","urlAudio":"https://fdfs.xmcdn.com/group33/M03/4A/6B/wKgJTFmxWwrxlHkaABxHq5G_lHo186.m4a"},{"title":"恒瑞医药点评（东兴）","urlAudio":"https://fdfs.xmcdn.com/group30/M09/19/B4/wKgJXlnLo0XCwVYrABw9Y6TAxpY370.m4a"},{"title":"恒瑞医药点评（中泰）","urlAudio":"https://fdfs.xmcdn.com/group30/M00/3E/FF/wKgJWlnLpPbzuMQPACRfocfri9Q731.m4a"},{"title":"我为什么看好恒瑞医药2（桥梁结构师）","urlAudio":"https://fdfs.xmcdn.com/group30/M06/40/A9/wKgJXlnM8rPAcEohABiOp_wdR6A354.m4a"},{"title":"我为什么看好恒瑞医药3（桥梁结构师）","urlAudio":"https://fdfs.xmcdn.com/group30/M06/41/8E/wKgJXlnM9cyyPfd1ACxKoasmAq8250.m4a"},{"title":"恒瑞医药点评（光大）","urlAudio":"https://fdfs.xmcdn.com/group30/M00/65/91/wKgJXlnOSNPj9jrBACxncF1-GyE515.m4a"},{"title":"恒瑞医药2010年报 管理层讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group32/M0B/43/52/wKgJnFnVqESg1xD1AGzn_nYmV5I750.m4a"},{"title":"恒瑞医药2011年报 管理层讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group30/M00/CF/B2/wKgJXlnVrNDh6pxXAGbR_MlIp5M069.m4a"},{"title":"恒瑞医药2012年报 经营情况讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group32/M02/42/F3/wKgJS1nVrSKTBl7QAMd8C8Ay1aM173.m4a"},{"title":"恒瑞医药2013年报 董事会报告","urlAudio":"https://fdfs.xmcdn.com/group31/M01/C1/86/wKgJX1nVtj7wTdazANoak985O44400.m4a"},{"title":"恒瑞医药2014年报董事会报告","urlAudio":"https://fdfs.xmcdn.com/group34/M02/20/0F/wKgJYVnXeHHTXheoAMRgKA9KKY4785.m4a"},{"title":"恒瑞医药2015年报 公司业务概要","urlAudio":"https://fdfs.xmcdn.com/group34/M01/1D/33/wKgJYFnXiQqgHBbQAGsH0J7PXW0279.m4a"},{"title":"恒瑞医药2017半年报 经营情况讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group34/M05/49/FD/wKgJYVnY4QKQ7aW7ACl-9PKfgZw667.m4a"},{"title":"恒瑞医药2015年报董事会报告","urlAudio":"https://fdfs.xmcdn.com/group34/M0B/43/D0/wKgJYFnY4Xug83ueASCsvMdTUNE031.m4a"},{"title":"恒瑞医药调研报告（国泰）","urlAudio":"https://fdfs.xmcdn.com/group34/M02/8F/DB/wKgJYFndZ6fQKglNABkbofNRAl0008.m4a"},{"title":"恒瑞医药三季报点评（东兴）","urlAudio":"https://fdfs.xmcdn.com/group34/M07/D5/08/wKgJYFnoll6iFDwuAA3AITFi5to755.m4a"},{"title":"恒瑞医药三季报点评（国信）","urlAudio":"https://fdfs.xmcdn.com/group34/M0A/D5/A1/wKgJYFnomDGwp-2QAB3J3f8erQ0415.m4a"},{"title":"恒瑞医药三季报点评（申万）","urlAudio":"https://fdfs.xmcdn.com/group34/M09/D6/23/wKgJYFnomeCyJQgZACTz8SSdrJU460.m4a"},{"title":"恒瑞医药三季报点评（国联）","urlAudio":"https://fdfs.xmcdn.com/group34/M05/D6/72/wKgJYFnomwSAPFazABIL_c-dKXg650.m4a"},{"title":"恒瑞医药三季报点评（中金）","urlAudio":"https://fdfs.xmcdn.com/group34/M0B/4B/8F/wKgJYVnonAHA2l4BABmOLM5gYJo854.m4a"},{"title":"恒瑞医药三季报点评（中泰）","urlAudio":"https://fdfs.xmcdn.com/group34/M07/4B/D2/wKgJYVnonPXQ5J_YABjAlynD7hA006.m4a"},{"title":"恒瑞医药三季报点评（上海）","urlAudio":"https://fdfs.xmcdn.com/group34/M00/63/1D/wKgJYVnpmj_yHll6ACNHKZcoFyA778.m4a"},{"title":"恒瑞医药三季报点评（招商）","urlAudio":"https://fdfs.xmcdn.com/group34/M03/EE/6E/wKgJYFnpmwyADExuABgGGFCXED8617.m4a"},{"title":"恒瑞医药三季报点评（东吴）","urlAudio":"https://fdfs.xmcdn.com/group34/M09/EE/8F/wKgJYFnpnHLxXfoZACTuE_LhRdY362.m4a"},{"title":"糖尿病的研发谁最强（黄建平）","urlAudio":"https://fdfs.xmcdn.com/group34/M04/68/01/wKgJYVnpyVux-Pp4ACCQmJUyW7A794.m4a"},{"title":"糖尿病的研发谁最强（黄建平）","urlAudio":"https://fdfs.xmcdn.com/group34/M04/F6/ED/wKgJYFnp5MnANeQRACCQmEVSR5M683.m4a"},{"title":"恒瑞的口服GLP-1是什么？（黄建平）","urlAudio":"https://fdfs.xmcdn.com/group34/M0B/6B/C2/wKgJYVnp5NzRAfQNACJNh27kLAA852.m4a"},{"title":"恒瑞医药三季报点评（交银）","urlAudio":"https://fdfs.xmcdn.com/group34/M0B/B7/DD/wKgJYFnxFBLgIGzFACj06TpYlYY097.m4a"},{"title":"恒瑞医药三季报点评（财通）","urlAudio":"https://fdfs.xmcdn.com/group34/M09/B8/3D/wKgJYFnxGcPgfwY-ABoPYsPuKOc593.m4a"},{"title":"恒瑞医药三季报点评（国泰）","urlAudio":"https://fdfs.xmcdn.com/group34/M06/B8/4E/wKgJYFnxGpiwNo6mABUR2BszcPs967.m4a"},{"title":"恒瑞医药三季报点评（兴业）","urlAudio":"https://fdfs.xmcdn.com/group34/M03/FC/DA/wKgJYFnz18nwzzDeAAxLI2_ZHek633.m4a"},{"title":"恒瑞的国际化走的有点猛","urlAudio":"https://fdfs.xmcdn.com/group29/M00/7F/77/wKgJXVpYfuWSkrSnAFDCYXOpUSg549.m4a"},{"title":"恒瑞医药加速成为国内领先国际一流的综合性药企（西南）","urlAudio":"https://fdfs.xmcdn.com/group42/M02/82/A9/wKgJ9FqYF_DAhUBGACtR56pNVfU928.m4a"},{"title":"恒瑞医药地氟烷获批准上市（中金）","urlAudio":"https://fdfs.xmcdn.com/group42/M09/99/7A/wKgJ9FqZPbCS8WhBABSVCRZSSdc062.m4a"},{"title":"恒瑞医药地氟烷首仿获批（东兴）","urlAudio":"https://fdfs.xmcdn.com/group42/M0A/9A/C8/wKgJ81qZPwjTtjqoABwIiNzjWrE797.m4a"},{"title":"恒瑞医药地氟烷首仿上市（华金）","urlAudio":"https://fdfs.xmcdn.com/group42/M04/B0/45/wKgJ81qaPo3TROHUACYj6Rs8U3o034.m4a"},{"title":"恒瑞医药首仿获批（天风）","urlAudio":"https://fdfs.xmcdn.com/group41/M03/AE/C2/wKgJ8VqaQAKiVezZACB8B28Z-wE559.m4a"},{"title":"恒瑞抗肿瘤药的开发和布局策略","urlAudio":"https://fdfs.xmcdn.com/group41/M03/DA/86/wKgJ8lqb3bTxKBDuAG543wQmpyM401.m4a"},{"title":"恒瑞医药地氟烷获批点评（广发）","urlAudio":"https://fdfs.xmcdn.com/group41/M01/EB/10/wKgJ8VqcvJbRqcCDABfROWYh9ao352.m4a"},{"title":"恒瑞医药仿制药双双落地创新药呼之欲出（国金）","urlAudio":"https://fdfs.xmcdn.com/group42/M07/F5/95/wKgJ81qdG7mit9GXAB59BtP6cAg756.m4a"},{"title":"恒瑞医药地氟烷获批点评（广发）","urlAudio":"https://fdfs.xmcdn.com/group41/M08/F7/29/wKgJ8lqdG-SQlDVoABfROWB6q3M637.m4a"},{"title":"恒瑞医药走向全球（中泰）","urlAudio":"https://fdfs.xmcdn.com/group42/M02/EB/CE/wKgJ81qcstbSMboRACbRMN4B8fA652.m4a"},{"title":"恒瑞医药点评（天风）","urlAudio":"https://fdfs.xmcdn.com/group42/M04/FE/4F/wKgJ81qrXFCCAk-yACF3JQW9Qzs310.m4a"},{"title":"恒瑞医药点评（中泰）","urlAudio":"https://fdfs.xmcdn.com/group41/M04/2B/D6/wKgJ8lq89bTAH4SRACJlB9csxv4019.m4a"},{"title":"恒瑞医药点评（西南）","urlAudio":"https://fdfs.xmcdn.com/group41/M04/29/57/wKgJ8Vq89cDjXBU_AB1UZDh72VM506.m4a"},{"title":"国内医药市场向头部企业集中是必然之事","urlAudio":"https://fdfs.xmcdn.com/group45/M0B/85/D4/wKgKlFtpco3DSNuTACFp7eBB7z8166.m4a"},{"title":"恒瑞医药点评（西南证券）","urlAudio":"https://fdfs.xmcdn.com/group45/M08/AA/A4/wKgKlFtsMV3DX6dwABhrazPTaIQ503.m4a"},{"title":"恒瑞医药半年报点评（雷公养老）","urlAudio":"https://fdfs.xmcdn.com/group45/M0A/B0/C9/wKgKlFtsx1qQ8e8aAAcS3SduHh4745.m4a"},{"title":"恒瑞医药点评（西南证券 ● 朱国广）","urlAudio":"https://fdfs.xmcdn.com/group47/M09/F0/9E/wKgKm1ts1lXBbfZeABrqLuw5SWA201.m4a"},{"title":"恒瑞医药半年报点评（中金.邹朋）","urlAudio":"https://fdfs.xmcdn.com/group45/M02/D1/40/wKgKlFtvg0GjoIyrAB6b3CE7FC4372.m4a"},{"title":"恒瑞医药半年报点评（招商证券.邱旻）","urlAudio":"https://fdfs.xmcdn.com/group48/M01/36/66/wKgKlVtvhC_DpZZgABb36Vjkzs0926.m4a"},{"title":"恒瑞医药半年报点评（国金证券.李敬雷）","urlAudio":"https://fdfs.xmcdn.com/group46/M04/E8/06/wKgKlltvhWGCO0xfAB085ygsPf4790.m4a"},{"title":"恒瑞医药半年报点评（兴业证券.徐佳熹）","urlAudio":"https://fdfs.xmcdn.com/group46/M07/E8/0D/wKgKlltvhguDBS24AA1U8EiRhOg602.m4a"},{"title":"恒瑞医药半年报点评（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group46/M0B/E8/1E/wKgKlltvh0vje-pEACCoFRrjJoQ809.m4a"},{"title":"恒瑞医药半年报点评（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group47/M00/D4/C2/wKgKk1tviJqiV6iDACER0ocl5_c530.m4a"},{"title":"恒瑞医药半年报点评（国泰君安.于溯洋）","urlAudio":"https://fdfs.xmcdn.com/group47/M0B/D4/CD/wKgKk1tvibDC8BNBABQrT07XA28140.m4a"},{"title":"恒瑞医药半年报点评（天风证券.郑薇）","urlAudio":"https://fdfs.xmcdn.com/group46/M02/E8/48/wKgKj1tvizSzGqhTACjBhmKHX08524.m4a"},{"title":"恒瑞医药超重磅砒洛替尼报产（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group45/M09/FD/27/wKgKjltvlzLyb7X5AGGlcr2Lv9M429.m4a"},{"title":"恒瑞医药19K观察（牛氓的胜利）","urlAudio":"https://fdfs.xmcdn.com/group48/M06/37/F0/wKgKlVtvnjvBDVXlAFriLQN412k645.m4a"},{"title":"恒瑞医药中报电话会纪要（静水流深道悟思净）","urlAudio":"https://fdfs.xmcdn.com/group47/M05/13/09/wKgKm1tvqcHRKCx9AGSihADfZyM598.m4a"},{"title":"恒瑞医药半年报点评（姚一刀）","urlAudio":"https://fdfs.xmcdn.com/group46/M05/0A/06/wKgKj1tyIz7SsF6lADYwmKlICg8927.m4a"},{"title":"恒瑞医药半年报点评（东兴证券.张金洋）","urlAudio":"https://fdfs.xmcdn.com/group45/M02/1E/78/wKgKjltyKhDSDbXgAAxhLNj39hA129.m4a"},{"title":"恒瑞医药地氟烷获首仿（医药云端信息）","urlAudio":"https://fdfs.xmcdn.com/group47/M01/F7/C2/wKgKk1tyOtDwBzCwACZP9_wVk4k098.m4a"},{"title":"恒瑞医药半年报点评（华金证券.郑巧）","urlAudio":"https://fdfs.xmcdn.com/group47/M08/F8/76/wKgKk1tyRcyAje_FACfK09Pio9I435.m4a"},{"title":"恒瑞医药半年报点评（中信建投.贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group48/M09/5A/89/wKgKlVtyR7TDbqPvADO5K1OPXak848.m4a"},{"title":"恒瑞医药半年报点评（东方财富.何伟）","urlAudio":"https://fdfs.xmcdn.com/group45/M08/F5/DC/wKgKlFtyS0rwszFGAB6Ug5H0E80060.m4a"},{"title":"恒瑞医药半年报点评（东吴证券.全铭）","urlAudio":"https://fdfs.xmcdn.com/group46/M04/0C/A0/wKgKj1tyTF_BRhnoABeg-7sHSuE871.m4a"},{"title":"恒瑞医药半年报点评（国联证券.周静）","urlAudio":"https://fdfs.xmcdn.com/group47/M04/F8/EC/wKgKk1tyTTzhs57aABMx43-PLp4243.m4a"},{"title":"恒瑞医药半年报点评（财通证券.张文录）","urlAudio":"https://fdfs.xmcdn.com/group46/M01/10/4A/wKgKlltyjzqBEg0mABq2ywxquzE609.m4a"},{"title":"恒瑞医药半年报点评（渤海证券.张冬明）","urlAudio":"https://fdfs.xmcdn.com/group45/M08/FB/1D/wKgKlFtyprnQGM70ACM_05w_ZLk983.m4a"},{"title":"恒瑞医药半年报点评（光大证券.林小伟）","urlAudio":"https://fdfs.xmcdn.com/group45/M03/4C/D8/wKgKjlt1gGDQiMw3ABrCixFtLUI763.m4a"},{"title":"恒瑞医药半年报点评（银河证券.李平祝）","urlAudio":"https://fdfs.xmcdn.com/group45/M05/4C/EF/wKgKjlt1gTTz_pnaABK9q68Mc1s443.m4a"},{"title":"恒瑞医药新药审批完毕点评（东吴证券.全铭）","urlAudio":"https://fdfs.xmcdn.com/group45/M04/22/76/wKgKlFt1gqXhq2BtABaVhcYhNJY383.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（广发证券.罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group45/M0B/70/17/wKgKlFt7xNHyN9VtABwi-H6vRGg767.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group47/M00/AF/AE/wKgKm1t7xiGhh0EnABxmgfWwb0I751.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（海通证券.余文心）","urlAudio":"https://fdfs.xmcdn.com/group47/M01/AF/C1/wKgKm1t7x3SjTi7KACQQVybQOI0987.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（招商证券.邱旻）","urlAudio":"https://fdfs.xmcdn.com/group48/M04/D5/CF/wKgKlVt7yzzAWPpPABmfyn83sw4118.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（光大证券.林小伟）","urlAudio":"https://fdfs.xmcdn.com/group45/M00/70/85/wKgKlFt7y12TQMcnAB0GkVTCsaQ169.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（中信建投.贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group48/M07/D5/A4/wKgKlVt7yMmDJ8c3ABz60UoBqwc046.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（申万宏源.闫天一）","urlAudio":"https://fdfs.xmcdn.com/group48/M0A/4F/79/wKgKnFt7zM7hF9tuAB7xCACvVzY697.m4a"},{"title":"恒瑞医药重磅新药吡咯替尼获批上市（中金.邹朋）","urlAudio":"https://fdfs.xmcdn.com/group47/M07/74/0A/wKgKk1t7zkuhVbKaABuC6LIil7E479.m4a"},{"title":"恒瑞医药白蛋白紫杉醇获批点评（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group47/M04/F7/36/wKgKm1uUhK7RdujcACJavoka_8Q326.m4a"},{"title":"恒瑞医药点评（光大证券.林小伟）","urlAudio":"https://fdfs.xmcdn.com/group48/M07/24/87/wKgKnFueNIGR7TwyABvlSE3Di8E647.m4a"},{"title":"恒瑞医药点评（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group45/M05/B3/AA/wKgKjlui_P2CjVTrACrGn5ANrew582.m4a"},{"title":"揭秘医药界最牛夫妻档（华夏时报.王俊仙）","urlAudio":"https://fdfs.xmcdn.com/group47/M0A/A5/BA/wKgKk1ukxU-RpE8fAEoj0CmnFEU472.m4a"},{"title":"恒瑞医药点评（中信建投.贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group48/M03/08/D5/wKgKlVukzb3hk3meAEExDhuKwQQ777.m4a"},{"title":"恒瑞医药点评（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group47/M05/E2/2E/wKgKm1ukztjQiQVVAB3VnU2VnJ0098.m4a"},{"title":"恒瑞医药点评(国金证券 ● 李敬雷）","urlAudio":"https://fdfs.xmcdn.com/group49/M0A/C8/22/wKgKl1u4JYuQdboTAB6vKMWJutQ346.m4a"},{"title":"恒瑞医药伊立替康进入优先审评点评（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group49/M06/BC/8B/wKgKmFvQZr-Tg9roABy4vq6JUG8507.m4a"},{"title":"恒瑞医药三季报点评（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group50/M01/E9/D1/wKgKmVvSrS7Q5L3cACZti8YfxZE012.m4a"},{"title":"恒瑞医药三季报点评（西南证券.朱国广）","urlAudio":"https://fdfs.xmcdn.com/group50/M00/E9/EE/wKgKmVvSroeToZIhACA1xOsqHko347.m4a"},{"title":"恒瑞医药三季报点评（招商证券.邱旻）","urlAudio":"https://fdfs.xmcdn.com/group49/M0B/EA/A2/wKgKmFvSrwGy6xtUABR6z0sRBCs033.m4a"},{"title":"恒瑞医药三季报点评（国泰君安.于溯洋）","urlAudio":"https://fdfs.xmcdn.com/group49/M01/05/87/wKgKmFvUDRSB3f86ABUR2AFi_kU924.m4a"},{"title":"恒瑞医药三季报点评（财通证券.张文录）","urlAudio":"https://fdfs.xmcdn.com/group49/M09/06/36/wKgKl1vUDiqwGyNoABTqa23BVko760.m4a"},{"title":"恒瑞医药三季报点评（东吴证券.全铭）","urlAudio":"https://fdfs.xmcdn.com/group50/M07/05/4A/wKgKnVvUDjvhZZA5ABb9_Tt7V9Y526.m4a"},{"title":"恒瑞医药现金牛四大金刚能否继续支撑股价高位运行（小柴研究）","urlAudio":"https://fdfs.xmcdn.com/group50/M06/05/D8/wKgKnVvUE8PDj-SrAHaFFXQXSrE966.m4a"},{"title":"恒瑞医药三季报点评（中国银河.李平祝）","urlAudio":"https://fdfs.xmcdn.com/group50/M04/58/EB/wKgKnVvX_GnzRkBEABJ3ZFawS2U528.m4a"},{"title":"恒瑞医药三季报点评（国泰君安.于溯洋）","urlAudio":"https://fdfs.xmcdn.com/group50/M05/3E/1F/wKgKnVvivSXwI12NABVMlTcWCF0221.m4a"},{"title":"恒瑞医药三季报点评（财通证券.张文录）","urlAudio":"https://fdfs.xmcdn.com/group50/M06/3E/2E/wKgKnVvivhjiBYouABWno0zKwmY899.m4a"},{"title":"恒瑞医药三季报点评（东吴证券.全铭）","urlAudio":"https://fdfs.xmcdn.com/group50/M03/3D/C8/wKgKmVviv2GBFIMtABcFHLKG5qw537.m4a"},{"title":"恒瑞医药三季报点评（中国银河证券.李平祝）","urlAudio":"https://fdfs.xmcdn.com/group49/M02/50/CE/wKgKmFvjoVzQaftYABPgoifHqBI961.m4a"},{"title":"恒瑞医药三季报点评（东兴证券.张金阳）","urlAudio":"https://fdfs.xmcdn.com/group49/M07/50/DB/wKgKmFvjogyBqNCYAA0LhH3YVFQ625.m4a"},{"title":"恒瑞医药三季报点评（广发证券.罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group51/M0A/4F/74/wKgKnlvjozHj00gQABjp6JY-9WM629.m4a"},{"title":"恒瑞医药三季报点评（海通证券.余文心）","urlAudio":"https://fdfs.xmcdn.com/group50/M06/57/04/wKgKnVvj_krh8Nu6AB1gWktaEvw041.m4a"},{"title":"恒瑞医药新药进度点评（海通证券.余文心）","urlAudio":"https://fdfs.xmcdn.com/group54/M07/B4/D3/wKgLclxBqOjh0dUiACPlfm81G_Q496.m4a"},{"title":"恒瑞医药新药进度点评（中信建投.贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group53/M03/B7/E5/wKgLcVxBqP7TFObyADGyjVsZQfM959.m4a"},{"title":"恒瑞医药点评（申万宏源.闫天一）","urlAudio":"https://fdfs.xmcdn.com/group53/M03/B6/5B/wKgLfFxBqQKykkJ-ACVO8gp_zEw339.m4a"},{"title":"恒瑞医药新药进度点评（中泰证券.江琦）","urlAudio":"https://fdfs.xmcdn.com/group54/M00/B4/6C/wKgLfVxBqzSS2snpAD41ax4Vlis779.m4a"},{"title":"恒瑞医药2018年报…业务概要","urlAudio":"https://fdfs.xmcdn.com/group57/M0B/B1/92/wKgLd1xmxL7ggR5fAEARL1ZVgfE614.m4a"},{"title":"恒瑞医药2018年报…核心竞争力分析","urlAudio":"https://fdfs.xmcdn.com/group56/M03/B2/00/wKgLgFxmxdfghckYABoJQJHRDI4497.m4a"},{"title":"恒瑞医药2018年报…经营情况讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group56/M01/B3/13/wKgLdlxmybyzLTAlAGrjD165pQk122.m4a"},{"title":"恒瑞医药2018年报…主要经营情况","urlAudio":"https://fdfs.xmcdn.com/group55/M0A/BA/BB/wKgLdVxnXkihSs5pADh3TiIJFWY992.m4a"},{"title":"恒瑞医药2018年报…行业和主要药品基本情况","urlAudio":"https://fdfs.xmcdn.com/group55/M06/BA/EF/wKgLdVxnYULDDNNHAEfDnJJLLoA354.m4a"},{"title":"恒瑞医药2018年报…药品生产销售情况","urlAudio":"https://fdfs.xmcdn.com/group57/M00/DE/5E/wKgLd1xo4jOSwiTxAFuifQTcD8I675.m4a"},{"title":"恒瑞医药2018年报…关于未来发展的讨论与分析","urlAudio":"https://fdfs.xmcdn.com/group55/M06/E0/12/wKgLdVxo7uiA5o-xAEmJXN3IKTc621.m4a"},{"title":"恒瑞医药2018年报点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group56/M02/FB/D5/wKgLgFxqLj7BfEHiACDYgJLvYHc049.m4a"},{"title":"恒瑞医药2018年报点评（财通证券张文录）","urlAudio":"https://fdfs.xmcdn.com/group55/M04/FC/8A/wKgLdVxqL3Sh0EIKABjlPuz4r2A003.m4a"},{"title":"恒瑞医药2018年报点评（天风证券郑薇）","urlAudio":"https://fdfs.xmcdn.com/group56/M01/FC/28/wKgLgFxqMZjAWkjcADxw7Tbl8no953.m4a"},{"title":"恒瑞医药2018年报点评（海通证券于文心）","urlAudio":"https://fdfs.xmcdn.com/group57/M02/FC/4C/wKgLgVxqM5zTV_hnACs3OVXBNrk048.m4a"},{"title":"恒瑞医药2018年报点评（兴业证券徐嘉熹）","urlAudio":"https://fdfs.xmcdn.com/group57/M0A/FC/5A/wKgLgVxqNG3ggiXHAA68pY1Y7ls690.m4a"},{"title":"恒瑞医药2018年报点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group55/M06/FD/23/wKgLdVxqNgWR2mTtACbbbOByH5M909.m4a"},{"title":"恒瑞医药2018年报点评（中信建投贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group55/M0B/18/05/wKgLf1xrW2uQgv4QABiHRZQ3dYg294.m4a"},{"title":"恒瑞医药2018年报点评（中金公司何子瑜）","urlAudio":"https://fdfs.xmcdn.com/group57/M00/17/9C/wKgLgVxrXKOjR--4AB-D0_qlOKc565.m4a"},{"title":"恒瑞医药2018年报点评（国信证券陈益凌）","urlAudio":"https://fdfs.xmcdn.com/group57/M06/18/75/wKgLd1xrZlzz5zLFAB9JF1MqgnI931.m4a"},{"title":"恒瑞医药2018年报点评（广发证券罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group57/M02/18/CC/wKgLgVxraCGR1tlQACpmsYUp_Q0002.m4a"},{"title":"恒瑞医药2018年报点评（国联证券周静）","urlAudio":"https://fdfs.xmcdn.com/group55/M00/27/34/wKgLf1xr7ObzxTiRABOJhWRNAKc483.m4a"},{"title":"恒瑞医药2018年报点评（华鑫证券杜永宏）","urlAudio":"https://fdfs.xmcdn.com/group56/M05/27/00/wKgLgFxr7geykJ3CABurwyPMoaM957.m4a"},{"title":"恒瑞医药2018年报点评（中国银河王晓琦）","urlAudio":"https://fdfs.xmcdn.com/group56/M0B/8D/B8/wKgLdlxwyhrSvZgzAB0pxJXsMhs904.m4a"},{"title":"孙飘扬：仿制药和创新要都要发展","urlAudio":"https://fdfs.xmcdn.com/group57/M09/C3/70/wKgLd1x_NEuwgpT-ACbPrM8IQkw165.m4a"},{"title":"恒瑞医药分析及股东大会小记（齐恒辉）","urlAudio":"https://fdfs.xmcdn.com/group55/M09/13/90/wKgLf1yDF7jw1LILAMbpJv7MmJ4466.m4a"},{"title":"恒瑞股东大会见闻（城南花已开_R）","urlAudio":"https://fdfs.xmcdn.com/group57/M09/16/35/wKgLd1yDPbagXg_dACqHOL2Y-ak460.m4a"},{"title":"恒瑞医药投资者交流会要点（椰子83）","urlAudio":"https://fdfs.xmcdn.com/group56/M07/16/C0/wKgLgFyDPkaQo0eGAAqudaSbMwA771.m4a"},{"title":"孙飘扬建议对新适应症和改良型制剂给予数据保护期","urlAudio":"https://fdfs.xmcdn.com/group56/M09/47/28/wKgLgFyFH7ywzYFlACrZcXEDEN8922.m4a"},{"title":"恒瑞医药为何越来越贵（阿尔法工厂）","urlAudio":"https://fdfs.xmcdn.com/group55/M01/14/1E/wKgLf1yOrJTwqkRlAEwXCDVNq98234.m4a"},{"title":"恒瑞医药2019一季报点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group58/M03/2E/6E/wKgLc1zHsemDMb34ACMWqODxdwQ936.m4a"},{"title":"恒瑞医药点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group61/M0B/0C/81/wKgMcF0PXqThXawPABs8XuDbhps288.m4a"},{"title":"恒瑞医药PD-1单抗获批上市点评（申万宏源闫天一）","urlAudio":"https://fdfs.xmcdn.com/group63/M01/0E/F1/wKgMcl0PX7WBlIkgABXHrXTEfa8940.m4a"},{"title":"恒瑞医药单PD-1抗获批上市点评（中金公司何子瑜）","urlAudio":"https://fdfs.xmcdn.com/group63/M04/0F/05/wKgMaF0PYQmAwlksAB0Jc10tbDI754.m4a"},{"title":"恒瑞医药卡瑞利珠单抗获批上市点评（广发证券罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group62/M08/1F/8A/wKgMcV0QM5mzIk-PABltzRVFXlw885.m4a"},{"title":"恒瑞医药卡瑞利珠单抗获批点评（光大证券林小伟）","urlAudio":"https://fdfs.xmcdn.com/group63/M0B/22/89/wKgMcl0QN2rAIcR7ABqNnzlxSds423.m4a"},{"title":"恒瑞医药卡瑞利珠单抗获批点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group62/M03/20/22/wKgMZ10QOY7D08mdADvA7bqk62M096.m4a"},{"title":"恒瑞医药卡瑞利珠单抗获批点评（西南证券朱国广）","urlAudio":"https://fdfs.xmcdn.com/group63/M0A/23/28/wKgMaF0QP7nx77nHAB_9s6oppaE873.m4a"},{"title":"恒瑞医药PD-1获批点评（兴业证券徐佳熹）","urlAudio":"https://fdfs.xmcdn.com/group63/M0A/B1/0D/wKgMaF0VjUSAiA_XAAyk3UvrU5s444.m4a"},{"title":"恒瑞医药PD-1获批点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group61/M0B/AE/8A/wKgMZl0VmwKSYrI1ACNr1KudSDU108.m4a"},{"title":"恒瑞医药PD-1获批点评（海通证券余文心）","urlAudio":"https://fdfs.xmcdn.com/group62/M06/AF/E8/wKgMcV0VnD2z5-mVACC_UsEodyQ519.m4a"},{"title":"恒瑞医药PD-1获批点评（安信证券马帅）","urlAudio":"https://fdfs.xmcdn.com/group62/M07/B0/08/wKgMZ10VnfLSLCs2AClHGca60Yc576.m4a"},{"title":"恒瑞医药引进三期唑类新药点评（广发证券罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group62/M06/B0/9C/wKgMcV0VoxKifHfUACKj5_xWqK8021.m4a"},{"title":"恒瑞医药食管癌二线治疗研究取得成功点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group64/M02/C3/1D/wKgMaV1ZNFqyUUUpADJM8fHzv1Q864.m4a"},{"title":"恒瑞医药PD-1单抗食管癌三期临床达到终点点评（中信建投贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group64/M06/C9/EC/wKgMaV1Z223RQn3_ADqAzuVy9Ww006.m4a"},{"title":"恒瑞医药食管鳞癌三期临床结果点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group66/M03/C9/E2/wKgMdV1Z3uLCmNdCADd2iC5Xy0I351.m4a"},{"title":"恒瑞医药食管癌三期临床达到终点点评（中金公司何子瑜）","urlAudio":"https://fdfs.xmcdn.com/group66/M09/C9/EF/wKgMdV1Z4DaCceyTABzjSI-Edeo878.m4a"},{"title":"恒瑞医药联合治疗肝细胞获批三期临床点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group64/M05/CA/09/wKgMc11Z4zqRqxKbADQ17bwMui0750.m4a"},{"title":"恒瑞医药2019年半年报-主要业务","urlAudio":"https://fdfs.xmcdn.com/group64/M01/FF/78/wKgMaV1wSeyiPyG4AA9lhlX38SI234.m4a"},{"title":"恒瑞医药2019年半年报-经营模式","urlAudio":"https://fdfs.xmcdn.com/group64/M00/FF/59/wKgMc11wSwuTzYrPABvZf6S92DM504.m4a"},{"title":"恒瑞医药2019年半年报-行业情况和业绩驱动因素","urlAudio":"https://fdfs.xmcdn.com/group66/M07/FF/22/wKgMdV1wS66xMH65AA1TaBMRVUo570.m4a"},{"title":"恒瑞医药2019年半年报-核心竞争力","urlAudio":"https://fdfs.xmcdn.com/group65/M06/FE/B2/wKgMal1wTKGwNOLyABjw_vdp5hU951.m4a"},{"title":"恒瑞医药2019年半年报-经营情况1","urlAudio":"https://fdfs.xmcdn.com/group66/M02/FF/36/wKgMdV1wTdPgKnMAABVxQG2eC7c084.m4a"},{"title":"恒瑞医药2019年半年报-经营情况2","urlAudio":"https://fdfs.xmcdn.com/group65/M09/FE/C4/wKgMdF1wTvWhRolLAB66pUVKLmY336.m4a"},{"title":"恒瑞医药2019年半年报-可能面对的风险","urlAudio":"https://fdfs.xmcdn.com/group66/M04/FF/4C/wKgMa11wUArxucI-ABd2IhVMKws713.m4a"},{"title":"恒瑞医药2019年半年报点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group65/M0A/85/AC/wKgMal15nAugrUTRACvRnHbL-Wc750.m4a"},{"title":"恒瑞医药2019年半年报点评（国金证券李敬雷）","urlAudio":"https://fdfs.xmcdn.com/group66/M02/86/26/wKgMa115nRyTk0fbABzUmEPXLfk242.m4a"},{"title":"恒瑞医药2019年半年报点评（中信建投贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group64/M06/E4/0C/wKgMaV2APSDB6iHqAEeq3sO6uOI846.m4a"},{"title":"恒瑞医药2019年半年报点评（兴业证券徐嘉熹）","urlAudio":"https://fdfs.xmcdn.com/group64/M07/E4/23/wKgMaV2APtKz6XzFAA4FGr1NXu4736.m4a"},{"title":"恒瑞医药2019年半年报点评（西南证券朱国广）","urlAudio":"https://fdfs.xmcdn.com/group65/M03/E3/39/wKgMdF2AQNqhYOrPACIIdGimD7s415.m4a"},{"title":"恒瑞医药2019年半年报点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group64/M06/45/2B/wKgMc12GqzOAHVSoACZr0S07LGA727.m4a"},{"title":"恒瑞医药2019年半年报点评（中金公司何子瑜）","urlAudio":"https://fdfs.xmcdn.com/group64/M04/45/24/wKgMaV2GrhuyefDnAB1aOcigJk8733.m4a"},{"title":"恒瑞医药2019年半年报点评（申万宏源闫天一）","urlAudio":"https://fdfs.xmcdn.com/group64/M0A/97/CC/wKgMaV2L503SCn6fABUtsqBhJ4s950.m4a"},{"title":"恒瑞医药2019年半年报点评（安信证券马帅）","urlAudio":"https://fdfs.xmcdn.com/group64/M08/97/EC/wKgMaV2L7A-wjwgzAEEvieH-lng514.m4a"},{"title":"恒瑞医药2019年半年报点评（华鑫证券杜永宏）","urlAudio":"https://fdfs.xmcdn.com/group65/M06/96/58/wKgMal2L7ULRKz84AACzYmEPUTU352.m4a"},{"title":"恒瑞医药2019年半年报点评（东北证券崔洁铭）","urlAudio":"https://fdfs.xmcdn.com/group66/M0A/E4/B6/wKgMdV2RPz3TKGweABXZgVj-ec0198.m4a"},{"title":"恒瑞医药2019年半年报点评（光大证券林小伟）","urlAudio":"https://fdfs.xmcdn.com/group65/M09/E3/F2/wKgMal2RQbSSGuBZADmYyVLC5nE739.m4a"},{"title":"恒瑞医药2019年半年报点评（国信证券陈益凌）","urlAudio":"https://fdfs.xmcdn.com/group65/M00/E4/09/wKgMdF2RQxOCVskxAB_mMxoyGg4462.m4a"},{"title":"恒瑞医药2019年半年报点评（华金证券周新明）","urlAudio":"https://fdfs.xmcdn.com/group66/M08/20/06/wKgMdV2WnhmAu6FaACFYPp3jVR4770.m4a"},{"title":"恒瑞医药2019年半年报点评（国盛证券张金洋）","urlAudio":"https://fdfs.xmcdn.com/group66/M06/1F/F8/wKgMa12Wn2ywTA4jAB58-SXD18s836.m4a"},{"title":"恒瑞医药2019年半年报点评（东兴证券胡博新）","urlAudio":"https://fdfs.xmcdn.com/group66/M09/20/09/wKgMa12WoLyiB24eABzXh0hQZJQ874.m4a"},{"title":"恒瑞医药2019年半年报点评（国泰君安丁单）","urlAudio":"https://fdfs.xmcdn.com/group64/M08/64/F2/wKgMaV2b9ifwDMupABWQFam84Ik701.m4a"},{"title":"恒瑞医药 源头活水不断 创新步伐加速（国盛证券张金洋）","urlAudio":"https://fdfs.xmcdn.com/group66/M09/64/04/wKgMdV2b-G2Ck7bCAC6A15tuMS8578.m4a"},{"title":"恒瑞医药：厚积薄发 六星闪耀（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group65/M00/63/88/wKgMdF2b-oLR7kALACt5gfoZWYk388.m4a"},{"title":"这家千亿药企的婚前财产，大都归了恒瑞的老板娘（阿尔法工场）","urlAudio":"https://fdfs.xmcdn.com/group65/M0B/91/72/wKgMdF2j7NHwgm_LACwfby_0E54730.m4a"},{"title":"微利时代 仿制药企转型创仿结合（北京商报郭秀娟）","urlAudio":"https://fdfs.xmcdn.com/group67/M0A/02/1D/wKgMbV2nqD3A9sStADlN5hNJCxU835.m4a"},{"title":"恒瑞医药两大适应症申请纳入优先审评点评1（国盛证券张金洋）","urlAudio":"https://fdfs.xmcdn.com/group69/M05/2B/AF/wKgMb12qVcHgb5UEACXWCu1E0PQ433.m4a"},{"title":"恒瑞医药2大适应症申请纳入优先审评点评2（国盛证券张金洋）P4","urlAudio":"https://fdfs.xmcdn.com/group68/M07/57/0E/wKgMbl2s9GORVh1-ACQmT3YIX9s766.m4a"},{"title":"恒瑞医药2大适应症申请纳入优先审评点评3（国盛证券张金洋）","urlAudio":"https://fdfs.xmcdn.com/group67/M08/9A/2D/wKgMd12w8DLR_W1HAChvPJxFUhA975.m4a"},{"title":"恒瑞医药2大适应症申请纳入优先审评点评4（国盛证券张金洋）完","urlAudio":"https://fdfs.xmcdn.com/group68/M05/9A/65/wKgMbl2w8WujvF3KABxiDhH8RXY841.m4a"},{"title":"恒瑞医药 十年磨剑 恒心致远（天风证券郑薇）","urlAudio":"https://fdfs.xmcdn.com/group69/M0B/C4/6E/wKgMeV2zuC6Q2KVBADzKtvArlsE487.m4a"},{"title":"恒瑞医药2019年三季报点评（安信证券马帅）","urlAudio":"https://fdfs.xmcdn.com/group69/M02/C4/8B/wKgMeV2zucrgAQrYAC4LKEnPs0M193.m4a"},{"title":"恒瑞医药2019年三季报点评（中泰证券江琦）","urlAudio":"https://fdfs.xmcdn.com/group67/M0B/C4/D5/wKgMd12zvKTipblOADgvkLcNDJ8266.m4a"},{"title":"恒瑞医药2019年三季报点评（广发证券罗佳荣）","urlAudio":"https://fdfs.xmcdn.com/group67/M06/02/C3/wKgMd123iQLBHyiQACkpu9IePxg566.m4a"},{"title":"恒瑞医药2019年三季报点评（东吴证券全铭）","urlAudio":"https://fdfs.xmcdn.com/group67/M07/02/CF/wKgMd123irOgCMdGAChKiLH5cpA975.m4a"},{"title":"恒瑞医药2019年三季报点评（中信建投贺菊颖）","urlAudio":"https://fdfs.xmcdn.com/group68/M06/02/6F/wKgMeF23jNeQEDUzAB5N-aZMkMA889.m4a"},{"title":"恒瑞医药2019年三季报点评（国信证券陈益凌）","urlAudio":"https://fdfs.xmcdn.com/group68/M01/30/40/wKgMbl26TduiknfvACCTej54z9k389.m4a"},{"title":"恒瑞医药2019年三季报点评（国盛证券张金洋）","urlAudio":"https://fdfs.xmcdn.com/group68/M0A/30/6C/wKgMeF26T4_hTpqPABqzz0kyJ7o402.m4a"},{"title":"恒瑞医药2019年三季报点评（国泰君安丁丹）","urlAudio":"https://fdfs.xmcdn.com/group68/M00/30/69/wKgMbl26ULOQUnzFABVfoZoAQEE970.m4a"},{"title":"恒瑞医药2019年三季报点评（兴业证券徐嘉熹）","urlAudio":"https://fdfs.xmcdn.com/group69/M0B/71/2A/wKgMb12-RESSxck3AA8EmoJ4t-o630.m4a"},{"title":"恒瑞医药2019年三季报点评（光大证券林小伟）","urlAudio":"https://fdfs.xmcdn.com/group67/M0B/70/FA/wKgMbV2-RjiTO7E-ADau0l71pxg702.m4a"},{"title":"恒瑞医药2019年三季报点评（华金证券周新明）","urlAudio":"https://fdfs.xmcdn.com/group69/M04/71/5C/wKgMeV2-R7qgrNPkACDc5kqzXV0741.m4a"},{"title":"恒瑞医药2019年三季报点评（申万宏源闫天一）","urlAudio":"https://fdfs.xmcdn.com/group68/M00/AF/9F/wKgMeF3CEjSDW1jRABktMyvn8X8355.m4a"},{"title":"恒瑞医药2019年三季报点评（中金公司何子瑜）","urlAudio":"https://fdfs.xmcdn.com/group67/M06/B0/64/wKgMbV3CE2bBm1EtAB8BInJW5mY460.m4a"},{"title":"恒瑞医药2019年三季报点评（西南证券朱国广）","urlAudio":"https://fdfs.xmcdn.com/group68/M08/C6/FB/wKgMbl3DjZHQU6tgACFDsenTKBo822.m4a"},{"title":"恒瑞医药2019年三季报点评（中国银河折佘宇）","urlAudio":"https://fdfs.xmcdn.com/group69/M0A/DC/E8/wKgMb13EqHqAF1daACGRg8SEoDU305.m4a"},{"title":"恒瑞医药2019年三季报点评（华鑫证券杜永宏）","urlAudio":"https://fdfs.xmcdn.com/group67/M00/F5/29/wKgMd13GO4ORvqTeABfrnIiY6y4393.m4a"},{"title":"恒瑞医药首个国产PARP抑制剂报产（光大证券林小伟）","urlAudio":"https://fdfs.xmcdn.com/group68/M03/F3/E3/wKgMbl3GPEzQ5PrJAB-lmJJAaXU302.m4a"},{"title":"恒瑞医药稀缺的医药创新王者（西南证券朱国广）","urlAudio":"https://fdfs.xmcdn.com/group68/M03/1B/56/wKgMeF3It7vBCpb7ADoxhD4VLrM286.m4a"},{"title":"恒瑞医药2019年三季报点评（招商证券吴斌）","urlAudio":"https://fdfs.xmcdn.com/group67/M0A/1C/4F/wKgMbV3IuHfRJ_xpABEvrLaD2pQ969.m4a"},{"title":"恒瑞医药引进干眼症新药（光大证券林小伟）","urlAudio":"https://fdfs.xmcdn.com/group69/M03/4C/34/wKgMb13LdJaTBET-ACymilZ6bbY116.m4a"},{"title":"恒瑞医药引进产品布局眼科领域（广发证券）","urlAudio":"https://fdfs.xmcdn.com/group68/M04/89/EC/wKgMeF3PNCKgp_A4AChUzOXd2rU352.m4a"},{"title":"恒瑞医药15年磨剑 创新仍在路上（东方证券）1","urlAudio":"https://fdfs.xmcdn.com/group67/M06/9F/71/wKgMd13QklehjpGEAB5ZuV0cwes484.m4a"},{"title":"恒瑞医药15年磨剑 创新仍在路上（东方证券）2","urlAudio":"https://fdfs.xmcdn.com/group69/M01/CC/59/wKgMb13THnbAp6K3ACrw8klJW-M599.m4a"},{"title":"恒瑞医药15年磨剑 创新仍在路上（东方证券）4","urlAudio":"https://fdfs.xmcdn.com/group67/M05/10/62/wKgMd13XQp6DvEE3AB3bcrtikSE593.m4a"},{"title":"恒瑞医药15年磨剑 创新仍在路上（东方证券）5","urlAudio":"https://fdfs.xmcdn.com/group68/M03/26/99/wKgMbl3Yv86Rwt32ACIqPd6XY5U987.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）6","urlAudio":"https://fdfs.xmcdn.com/group69/M01/3B/1D/wKgMb13Z72rBrIMMACx0m69HKak319.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）7","urlAudio":"https://fdfs.xmcdn.com/group69/M08/54/27/wKgMb13bYwKQB4E-ACLhyfh8sr0835.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）8","urlAudio":"https://fdfs.xmcdn.com/group67/M07/80/5D/wKgMbV3duU2DWv0gACJjg0qWTmk456.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）9","urlAudio":"https://fdfs.xmcdn.com/group69/M05/99/99/wKgMb13fGbnirBV2ACO1QLGvrkw459.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）10","urlAudio":"https://fdfs.xmcdn.com/group69/M01/B1/6A/wKgMb13gdBuiU-CkABnsGLz_GeY565.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）11","urlAudio":"https://fdfs.xmcdn.com/group69/M09/F0/C7/wKgMeV3juvOy-barACLpI5uUg_0719.m4a"},{"title":"恒瑞医药15年磨剑 创新仍始于上（东方证券）12完","urlAudio":"https://fdfs.xmcdn.com/group69/M0B/18/91/wKgMeV3mIVfA_bcoACvabfo1XGY310.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）1","urlAudio":"https://fdfs.xmcdn.com/group69/M03/42/45/wKgMb13oScPTE7MfACR-aprgUJs544.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）2","urlAudio":"https://fdfs.xmcdn.com/group68/M04/59/D1/wKgMeF3pptninN2xACZP6ltQveI555.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）3","urlAudio":"https://fdfs.xmcdn.com/group67/M0A/83/4A/wKgMd13sKm6SNUH6ACUl04vvnsc046.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）4","urlAudio":"https://fdfs.xmcdn.com/group68/M00/98/4F/wKgMeF3titbDr-m8ACYSvs77J_4976.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）5","urlAudio":"https://fdfs.xmcdn.com/group64/M0B/AC/59/wKgMc13wLw_yrZJaACT5xhq-L9s512.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）6","urlAudio":"https://fdfs.xmcdn.com/group69/M08/BF/06/wKgMeV3yEYDRaw34ACQ9z4nIClk704.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）7","urlAudio":"https://fdfs.xmcdn.com/group54/M09/F9/0E/wKgLcl31msPysSQ0ACmHtHbVGdA709.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）8","urlAudio":"https://fdfs.xmcdn.com/group53/M05/0B/1F/wKgLcV36wqTR5I_VABBcNfRUOs4421.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）9","urlAudio":"https://fdfs.xmcdn.com/group59/M00/66/A7/wKgLel36xPPDSzNOACbMvezcgnc423.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）10","urlAudio":"https://fdfs.xmcdn.com/group55/M00/69/A5/wKgLdV39ZC2RyWMcACs71VQ9rUk865.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）11","urlAudio":"https://fdfs.xmcdn.com/group70/M04/2B/E4/wKgO2F4C1JLS3mkhAClS2ZYTigI990.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）12","urlAudio":"https://fdfs.xmcdn.com/group72/M08/A2/FF/wKgO0F4FUOmCXYRwACgG-tMfv10725.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）13","urlAudio":"https://fdfs.xmcdn.com/group70/M0A/7E/D8/wKgO2F4IbrHwbJxHACu8CoZon20095.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）14","urlAudio":"https://fdfs.xmcdn.com/group71/M00/8B/AB/wKgOz14Ja-qAUTcrADBlbdzKi70245.m4a"},{"title":"恒瑞医药-生物医药行业2020年度策略（平安证券）15完","urlAudio":"https://fdfs.xmcdn.com/group72/M0B/59/2B/wKgO0F4L_kXhM1bTACOe9nOBFD0215.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）1","urlAudio":"https://fdfs.xmcdn.com/group70/M0A/D5/26/wKgOzl4OhVmCSYO5ACc9zJC5OPo634.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）2","urlAudio":"https://fdfs.xmcdn.com/group72/M05/E7/AD/wKgO0F4RLrfDbLyJADAgZwADNWM268.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）3","urlAudio":"https://fdfs.xmcdn.com/group72/M0A/0C/C7/wKgO0F4SikryZSXzACck2Jt6Lqg276.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）4","urlAudio":"https://fdfs.xmcdn.com/group70/M09/33/7C/wKgOzl4VVdbBH-ACACshZgBKEwU274.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）5","urlAudio":"https://fdfs.xmcdn.com/group71/M00/54/E5/wKgO2V4XyWiTdfSqACvTla6tfQY860.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）6","urlAudio":"https://fdfs.xmcdn.com/group72/M0B/C4/A2/wKgO0F4ZI-3SWvFBAC60i0BYJTk895.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）7","urlAudio":"https://fdfs.xmcdn.com/group72/M05/10/EB/wKgO0F4b4CDA2UHRACcaOfcrIWo368.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）8","urlAudio":"https://fdfs.xmcdn.com/group70/M00/BA/7A/wKgOzl4efKOB8NITACTy1qGfEXM675.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）9","urlAudio":"https://fdfs.xmcdn.com/group71/M03/D1/B5/wKgO2V4f5Emjf320ADAQ5oKOy1M320.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）10","urlAudio":"https://fdfs.xmcdn.com/group71/M08/FB/BF/wKgO2V4idanBJ5g1ACxuveHkdRg799.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略（财通证券）11","urlAudio":"https://fdfs.xmcdn.com/group72/M05/34/2E/wKgO0F4lGzeBY0dCADPE3uxnKfI396.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略-美年健康（财通证券）12","urlAudio":"https://fdfs.xmcdn.com/group72/M09/84/04/wKgO0F4nrD7CoszzACSBXd2Byts902.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略-泰格（财通证券）13","urlAudio":"https://fdfs.xmcdn.com/group70/M00/81/9F/wKgO2F4rq6uwWLFSACMN13j1Ozk197.m4a"},{"title":"恒瑞医药-医药生物行业2020年度策略-康弘药业（财通证券）14完","urlAudio":"https://fdfs.xmcdn.com/group72/M02/E1/00/wKgO0F4ziKHDlXdTAB02mdOOHO4377.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）1","urlAudio":"https://fdfs.xmcdn.com/group72/M0B/94/C9/wKgO0F43he-AUv2CACN2-IyjcQ4844.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）2","urlAudio":"https://fdfs.xmcdn.com/group71/M00/C2/7F/wKgO2V47eJjSSKh7ACYK5Chz3qg298.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）3","urlAudio":"https://fdfs.xmcdn.com/group71/M07/27/97/wKgO2V4_UQKyon45AC1dz_4kBp8957.m4a"},{"title":"恒瑞医药-医药行业深度研究 国药股份&上海医药（中信建投）4","urlAudio":"https://fdfs.xmcdn.com/group70/M04/4D/E6/wKgOzl5AtVbQhXBFACvqrahfbGQ818.m4a"},{"title":"恒瑞医药-医药行业深度研究-沃森生物（中信建投）5","urlAudio":"https://fdfs.xmcdn.com/group72/M0A/FB/70/wKgO0F5Dil7hwVWjACgYAA7M-d8544.m4a"},{"title":"恒瑞医药-医药行业深度研究-厦门万泰（中信建投）6","urlAudio":"https://fdfs.xmcdn.com/group75/M0B/04/0A/wKgO015GBsWgs3bjACpPa3cWXNw918.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）7","urlAudio":"https://fdfs.xmcdn.com/group78/M01/2C/9B/wKgO1l5IiLLTBqh6ACblsXbjrIQ856.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）8","urlAudio":"https://fdfs.xmcdn.com/group78/M05/4F/BC/wKgO1l5LLsminFDVACTlNAp6hmU920.m4a"},{"title":"恒瑞医药-医药行业深度研究（中信建投）9","urlAudio":"https://fdfs.xmcdn.com/group76/M05/6D/5B/wKgO1F5N4t_zEaVrACpWHjD-PBk869.m4a"},{"title":"恒瑞医药-医药行业深度研究-高值耗材（中信建投）10","urlAudio":"https://fdfs.xmcdn.com/group74/M06/98/35/wKgO0l5QlxbyZEjLACSGNMCuFIs314.m4a"},{"title":"恒瑞医药-医药行业深度研究-投资建议（中信建投）11完","urlAudio":"https://fdfs.xmcdn.com/group78/M0A/D1/22/wKgO1l5Ubm2BbVBXACmdvabXiYk527.m4a"},{"title":"恒瑞医药-新人辈出基业长青：全球最佳医药资产之一（申万宏源）1","urlAudio":"https://fdfs.xmcdn.com/group77/M05/FA/F2/wKgO1V5XBDrQvoRCAC8bbGBAlIY738.m4a"},{"title":"恒瑞医药-新人辈出基业长青：全球最佳医药资产之一（申万宏源）2","urlAudio":"https://fdfs.xmcdn.com/group76/M06/2E/84/wKgO3l5a7cnSfBJYACUT8NBYhWI545.m4a"},{"title":"恒瑞医药-新人辈出基业长青：全球最佳医药资产之一（申万宏源）3","urlAudio":"https://fdfs.xmcdn.com/group77/M0B/50/7D/wKgO315dvYKSUpi1ACa-SqAzJk0182.m4a"},{"title":"恒瑞医药-新人辈出基业长青：全球最佳医药资产之一（申万宏源）4","urlAudio":"https://fdfs.xmcdn.com/group76/M02/AD/83/wKgO3l5jBciBHyKGACYj8DD639k821.m4a"},{"title":"恒瑞医药-新人辈出基业长青：全球最佳医药资产之一（申万宏源）5","urlAudio":"https://fdfs.xmcdn.com/group78/M05/FA/B0/wKgO1l54cOXCmjM_ACliOsJxv00699.m4a"}]